Clinicopathological Reclassification of Idiopathic Inflammatory Myopathy to Match the Serological Results of Myositis-Specific Antibodies.

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Journal of Clinical Neurology Pub Date : 2024-01-01 DOI:10.3988/jcn.2022.0432

Young-Eun Park, Dae-Seong Kim, Minsung Kang, Jin-Hong Shin

{"title":"Clinicopathological Reclassification of Idiopathic Inflammatory Myopathy to Match the Serological Results of Myositis-Specific Antibodies.","authors":"Young-Eun Park, Dae-Seong Kim, Minsung Kang, Jin-Hong Shin","doi":"10.3988/jcn.2022.0432","DOIUrl":null,"url":null,"abstract":"Background and purpose: Advances in serological tests are transforming the classification of idiopathic inflammatory myopathy (IIM). The new criteria suggested by the 119th European Neuromuscular Center international workshop divide IIM cases into four main diseases according to clinical and pathological findings, adding immune-mediated necrotizing myositis and nonspecific myositis to the classic categories of polymyositis and dermatomyositis.Methods: Seventy one cases of IIM with sufficient available clinical and pathological data were reviewed to be reclassified according to the new criteria.Results: Most of the cases previously classified as polymyositis (77.8%, 35/45) were reclassified as immune-mediated necrotizing myopathy. The results of myositis-specific antibodies matched well with the new clinicopathological classification.Conclusions: This new clinicopathological classification for IIM in combination with serological test results could be applied to our previous case series. Adoption of the new criteria will lead to a better understanding of the disease and hence new therapeutic insights.","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"20 1","pages":"67-77"},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782087/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3988/jcn.2022.0432","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: Advances in serological tests are transforming the classification of idiopathic inflammatory myopathy (IIM). The new criteria suggested by the 119th European Neuromuscular Center international workshop divide IIM cases into four main diseases according to clinical and pathological findings, adding immune-mediated necrotizing myositis and nonspecific myositis to the classic categories of polymyositis and dermatomyositis.

Methods: Seventy one cases of IIM with sufficient available clinical and pathological data were reviewed to be reclassified according to the new criteria.

Results: Most of the cases previously classified as polymyositis (77.8%, 35/45) were reclassified as immune-mediated necrotizing myopathy. The results of myositis-specific antibodies matched well with the new clinicopathological classification.

Conclusions: This new clinicopathological classification for IIM in combination with serological test results could be applied to our previous case series. Adoption of the new criteria will lead to a better understanding of the disease and hence new therapeutic insights.

查看原文本刊更多论文

根据肌炎特异性抗体的血清学结果对特发性炎症性肌病进行临床病理重新分类

背景和目的：血清学检验的进步正在改变特发性炎症性肌病（IIM）的分类。第119届欧洲神经肌肉中心国际研讨会提出的新标准根据临床和病理结果将特发性炎症性肌病分为四大类，在经典的多发性肌炎和皮肌炎的基础上增加了免疫介导的坏死性肌炎和非特异性肌炎：对 71 例有足够临床和病理资料的 IIM 病例进行了审查，以便根据新标准重新分类：结果：大多数之前被归类为多发性肌炎的病例（77.8%，35/45）被重新归类为免疫介导的坏死性肌病。肌炎特异性抗体的检测结果与新的临床病理分类十分吻合：结论：结合血清学检测结果的 IIM 新临床病理分类法适用于我们之前的病例系列。采用新标准将有助于更好地了解该疾病，从而获得新的治疗见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neurology 医学-临床神经学

CiteScore

4.50

自引率

6.50%

发文量

审稿时长

>12 weeks

期刊介绍： The JCN aims to publish the cutting-edge research from around the world. The JCN covers clinical and translational research for physicians and researchers in the field of neurology. Encompassing the entire neurological diseases, our main focus is on the common disorders including stroke, epilepsy, Parkinson''s disease, dementia, multiple sclerosis, headache, and peripheral neuropathy. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, and letters to the editor. The JCN will allow clinical neurologists to enrich their knowledge of patient management, education, and clinical or experimental research, and hence their professionalism.